Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZLAB vs APLS: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

APLS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 10–0 Matrix Metrics)

APLS Overall Winner 6-Pillar Tally: ZLAB 1 – 5 APLS Matrix Metrics: ZLAB 0 – 10 APLS

As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZLAB vs APLS
ZLAB NASDAQ
Zai Lab Limited American Depositary Shares
Pharmaceutical Preparations
$23.83
-3.13% 1D
Market Cap $3.0B
TTM Revenue $442M
Forward P/E N/M
Beta / 30D Vol 1.19β · 78% Vol
Unified Composite Score
47.4 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 53.5
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 47
RSI-14: 47.1 · SMA20: $23.97 · SMA50: $24.57
APLS NASDAQ Head-to-Head Winner
Apellis Pharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$41.03
-0.07% 1D
Market Cap $5.3B
TTM Revenue $1.11B
Forward P/E 46.3x
Beta / 30D Vol 4.54β · 2% Vol
Unified Composite Score
60.2 / 100 BUY
Tech 40.0 Fund 52.0 Flow 67.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.4% over 20 days), RSI 84
RSI-14: 84.5 · SMA20: $40.97 · SMA50: $32.36

6-Pillar Scorecard Institutional Category Breakdown (ZLAB 1 – 5 APLS)

Columns: Metric · ZLAB · APLS
1. Valuation Multiples APLS
Forward P/E N/M 46.3x
Trailing P/E N/M 38.3x
PEG Ratio N/M N/M
EV / Revenue 6.8x 4.8x
2. Growth & Scale APLS
Revenue Growth (YoY) -6.8% +60.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $442M $1.11B
Market Cap $3.0B $5.3B
3. Profitability & Quality APLS
Gross Margin 0.6% 64.3%
Operating Margin -63.0% 9.9%
Net Profit Margin -44.9% 12.1%
Return on Equity (ROE) -30.0% 46.0%
4. Balance Sheet & Cash Flow APLS
Cash Generation (TTM) -$262M EBITDA $167M EBITDA
Cash Flow Margin -59.3% EBITDA Mgn 15.1% EBITDA Mgn
Net Cash / Leverage $5.01 Book/Sh · -30.0% ROE $3.24 Book/Sh · 46.0% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning APLS
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 58.4% (58th %ile) 0.3% (<1st %ile)
Put/Call OI Skew Thin ADR Chain 0.89x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markup
6. R&D & Supply-Chain Moat ZLAB
OpEx & R&D Intensity 63.6% of Rev ($281M) 54.4% of Rev ($601M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZLAB (0) vs APLS (10)
Institutional Metric ZLAB APLS Criterion Row Edge
Market Capitalization
Scale
$3.0B $5.3B Larger Scale APLS
Trailing P/E Ratio
Valuation
N/M 38.3x Lower Multiple APLS
Forward P/E Ratio
Valuation
N/M 46.3x Lower Multiple APLS
Revenue Growth (YoY)
Growth
-6.8% +60.9% Higher Growth APLS
Operating Margin (TTM)
Profitability
-63.0% 9.9% Higher Margin APLS
Net Profit Margin
Profitability
-44.9% 12.1% Higher Margin APLS
Return on Equity (ROE)
Capital Efficiency
-30.0% 46.0% Higher ROE APLS
52-Week Range Position
Momentum
60% ($16–$29) 100% ($16–$41) Stronger Trend APLS
Beta / 30D Volatility
Risk Regime
1.19β · 78% Vol 4.54β · 2% Vol Lower Realized Risk APLS
Unified Institutional Score
Composite Signal
47.4 / 100 (HOLD) 60.2 / 100 (BUY) Higher Composite APLS
Trailing 12M Revenue (USD)
Operating Scale
$442M $1.11B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
0.6% 64.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 6.8x EV/Rev N/M PEG · 4.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$262M EBITDA ($5.01 Book/Sh · -30.0% ROE) $167M EBITDA ($3.24 Book/Sh · 46.0% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon APLS +7.23 pp
ZLAB: -6.79% · APLS: +0.44%
3M Horizon APLS +76.34 pp
ZLAB: +7.57% · APLS: +83.91%
6M Horizon APLS +112.92 pp
ZLAB: -5.8% · APLS: +107.12%
1Y Horizon APLS +112.92 pp
ZLAB: -5.8% · APLS: +107.12%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZLAB vs APLS. Trailing 12-month operating profitability (ZLAB -63.0% vs APLS 9.9%) and valuation multiples (ZLAB N/M vs APLS 46.3x Forward P/E) are benchmarked directly in Pillar 4 below.

ZLAB ADR TTM Benchmark FX-Normalized USD
TTM Revenue$442M
Gross Margin0.6%
Op. Margin-63.0%
ROE / Fwd P/E-30.0% · N/M
APLS ADR TTM Benchmark FX-Normalized USD
TTM Revenue$1.11B
Gross Margin64.3%
Op. Margin9.9%
ROE / Fwd P/E46.0% · 46.3x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZLAB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 58.4%
IV Percentile 58th %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ZLAB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
APLS UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 0.3%
IV Percentile <1st %ile
Put/Call OI Skew 0.89x (Balanced)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact APLS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZLAB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment 63.6% of Rev ($281M)
90D Engineering Disclosures 0 Published
APLS Moat Profile High-Margin Pricing Power Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $5.3B market capitalization and 9.9% operating margin.
OpEx & R&D Reinvestment 54.4% of Rev ($601M)
90D Engineering Disclosures 0 Published

Investor FAQ ZLAB vs APLS Key Questions & Quantitative Answers

As of Nov 16, 2026, Apellis Pharmaceuticals, Inc. (APLS) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 10–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZLAB carries a Unified Composite Score of 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin), whereas APLS carries 60.2/100 (BUY) at $41.03 (46.3x Forward P/E, 9.9% operating margin). Technically, ZLAB sits in a Neutral phase (RSI 47.1, UNCLASSIFIED options structure) and APLS sits in a Markup phase (RSI 84.5, UNCLASSIFIED options structure).

APLS leads the Growth & Scale pillar: ZLAB posts -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin), compared with APLS at +60.9% YoY revenue growth and +0.0% YoY earnings growth on $1.11B TTM revenue (64.3% gross margin, 9.9% operating margin). On trailing 12-month operating scale, ZLAB generates $442M in USD-normalized revenue versus $1.11B for APLS. In operating R&D and SG&A reinvestment, ZLAB deploys 63.6% of Rev ($281M) (0 90-day corporate R&D disclosures) versus 54.4% of Rev ($601M) (0 disclosures) for APLS.

APLS screens cheaper on headline valuation multiples. ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin), whereas APLS trades at 46.3x Forward P/E, 38.3x Trailing P/E, N/M PEG, and 4.8x EV/Revenue (15.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZLAB (-30.0% ROE) versus APLS (46.0% ROE) capital efficiency.

In options market volatility and institutional positioning, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk). By comparison, APLS carries 0.3% implied volatility (<1st %ile, Compressed (<25th %ile)), a 0.89x (Balanced) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.54β · 2% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.